Undisclosed SCHOOL-based programs
Cancer, Atherosclerosis, Autoimmune Diseases, Retinopathy, Inflammatory Diseases
Pre-clinicalActive
Key Facts
Indication
Cancer, Atherosclerosis, Autoimmune Diseases, Retinopathy, Inflammatory Diseases
Phase
Pre-clinical
Status
Active
Company
About SignaBlok
SignaBlok is a private, preclinical-stage biotech developing a new class of peptide drugs and targeted nanosystems based on its foundational SCHOOL platform for cell receptor signaling. The company's approach, inspired by viral evasion mechanisms, aims to disrupt pathological immune responses by modulating macrophage activity in a range of serious inflammatory and immune diseases. Led by its founder and CEO, Dr. Alexander B. Sigalov, the firm is built on a strong IP portfolio and academic research but operates as a pre-revenue entity with an undisclosed pipeline stage and financial backing.
View full company profile